Obesity elevates hepatic and circulating PAI-1 levels in mice. (A-B) Plasma PAI-1 levels (A) and their associations with BMI (B) among individuals (N = 12). (C) Plasma α2-AP, tPA, Plg and fibrinogen levels in individuals (N = 12). (D-E) Plasma PAI-1 levels (D) and their association with weights (E) in mice fed an ND or an HFD for 4 months. (F) Plasma α2-AP, tPA, Plg and fibrinogen levels in mice (N = 12). (G-H) Liver Serpine1 mRNA levels (G) and their associations with plasma PAI-1 (H) levels (N = 12) in mice. (I) Livers of mice were assayed for PAI-1 protein and the GAPDH loading control by immunoblotting with densitometric quantification shown (N = 5). (J-K) C57BL/6J mice were fed an HFD for 4 months, followed by injection with either AAV8-TBG-shSerpine1 or AAV8-TBG-Zsgreen: (J) plasma PAI-1 levels (N = 4); (K) thrombus weight and length (N = 5). The data are represented as the mean ± SEM, n.s. P > .05; ∗∗P < .01; ∗∗∗P < .001 vs ND group or HFD mice with AAV8-TBG-Zsgreen group. BMI, body mass index; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NM, normal weight; n.s., no significance; OB, obese.